RxDoctor Payments Data

William Zeichner, MD

Surgery · Natchitoches, LANPI 1861483869

Payments from drug & device makers

$1,357in general payments, 2019–2025

Across 24 payments — averaging $56.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Reapplix Inc.$739
  • Kerecis Limited$300
  • Lilly USA, LLC$90
  • Pfizer$70
  • Novartis$38
  • Intuitive Surgical$27
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$1,357100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,357 in reported general payments places this provider in the 45th percentile of 381 surgery providers in Louisiana.

See all surgery providers in Louisiana

Medicare billing

Part B allowed, 2024
$103,773
Medicare patients
190
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide33$40,445
JardianceEmpagliflozin33$29,745
JanuviaSitagliptin Phosphate26$14,458
TrulicityDulaglutide14$13,105
EliquisApixaban12$10,475
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl46$9,596
Buprenorphine Hcl23$2,563
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp13$1,495
Ventolin HfaAlbuterol Sulfate12$981
Potassium Chloride91$955
Gabapentin111$823
Ezetimibe59$821
Baclofen17$686
Albuterol Sulfate HfaAlbuterol Sulfate24$627
Omeprazole115$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$90$53,55047 claims
PfizerEliquis$70$10,47512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 381 surgery providers in Louisiana.

Other surgery in Natchitoches

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →